Rejuve.Bio
Rejuve Biotech builds Mozi, an AI co-scientist platform using neural-symbolic AI and a biomedical knowledge graph to accelerate drug discovery for aging and age-related diseases, targeting pharmaceutical and biotech research organizations through an invite-only beta program.
- Company typePrivate
- Founded2022
- HeadquartersOrange, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Rejuve.Bio does
Rejuve Biotech (operating as Rejuve.Bio) is a privately held AI-driven biomedical research company founded in 2022 and headquartered in Orange, California. The company's core product is Mozi, an AI co-scientist platform that unifies genetic, clinical, and preclinical datasets into a structured knowledge graph, generates testable hypotheses about biological pathways and candidate treatments using neural-symbolic AI, and validates those hypotheses against biological systems (Methuselah Fly outcomes) and human health data from the affiliated Rejuve Network. The platform is positioned to accelerate drug discovery for aging and age-related diseases — including Alzheimer's and cardiovascular decline — by addressing three structural problems in the field: high development cost (billions of dollars), long timelines (years of trial and error), and siloed datasets that do not connect across species, labs, and populations.
The primary stated customer segment is pharmaceutical companies and biotech research organizations seeking AI-augmented drug discovery capabilities. The company operates an invite-only beta testing program accessed via direct email ([email protected]), has no publicly disclosed pricing, and appears to be in early commercialization. A related consumer-facing initiative, Rejuve.AI, was launched in June 2025 as a token-incentivized app intended to collect holistic genomic, clinical, lifestyle, and psychological health data from individuals, feeding a data flywheel that supports the research platform. Rejuve Biotech is venture-backed, having raised $288,551 in a December 2024 funding round (investors undisclosed), has between 1 and 10 employees, and joined the Lifespan Alliance in August 2024 as part of a broader longevity-research coalition.
Rejuve.Bio firmographics
Firmographics- Name
- Rejuve.Bio
- Legal name
- Rejuve Biotech
- Website
- https://rejuve.bio
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Rejuve Biotech builds Mozi, an AI co-scientist platform using neural-symbolic AI and a biomedical knowledge graph to accelerate drug discovery for aging and age-related diseases, targeting pharmaceutical and biotech research organizations through an invite-only beta program.
- Ownership category
- akta.pro rank
Rejuve.Bio industry classification
Industry- Product category
- AI-driven drug discovery platform
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Rejuve.Bio is headquartered
LocationHeadquarters
- HQ city
- Orange
- HQ country
- United States
- HQ region
- North America
Markets served
Rejuve.Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Rejuve.Bio product offering
Product offeringCore offering
Rejuve.Bio builds and operates Mozi, an AI-driven biomedical research platform that unifies genetic, clinical, and preclinical datasets into a knowledge graph, generates testable therapeutic hypotheses using neural-symbolic AI, and validates them against Methuselah Fly outcomes and human health data from the Rejuve Network. The company targets pharmaceutical and biotech researchers working on aging and age-related diseases, and supplements this enterprise platform with the consumer-facing Rejuve.AI app that collects token-incentivized holistic health data.
Product overview
Rejuve.Bio is building an AI-driven research platform focused on translational medicine and therapeutic discovery for aging and age-related diseases. The core offering is Mozi, an AI co-scientist platform that unifies datasets, generates hypotheses, and validates findings. Additionally, the company operates Rejuve.AI (referenced in affiliated news), a consumer-facing longevity research app that collects health data through token-based incentives. The two products serve different segments: Mozi for biomedical researchers and drug discovery, and Rejuve.AI for consumer health data contribution.
Differentiator
Problem solved
Functional benefit
Brands
- Mozi: AI co-scientist platform developed by Rejuve Biotech that builds structured knowledge, generates testable hypotheses, and validates them with living systems.
Products and services
- Mozi AI co-scientist platform that builds structured knowledge, generates testable hypotheses, and validates them with living systems to discover interventions for aging and age-related diseases; targeted at pharmaceutical and biotech research organizations.
- Rejuve.AI App Consumer-facing longevity research application that uses token-based incentives to gather holistic health data (genomic, clinical, lifestyle, psychological) from users to support AI-driven longevity research.
Quantifiable outcome
- Aims to build the world's largest corpus of holistic health data across people's lifespans
Companies that use Rejuve.Bio
Customer profileSegments1 record
Ideal customer profiles1 record
Rejuve.Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Rejuve.Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Lifespan AlliancecoreRejuve Biotech joined the Lifespan Alliance, a coalition focused on longevity research and interventions. The Lifespan Alliance is associated with Lifespan.io, an organization dedicated to accelerating longevity science. This partnership positions Rejuve Biotech within a broader ecosystem of longevity-focused entities.
Recent moves5 records
Expansion highlights5 records
Rejuve.Bio competitors and assessment
Company assessmentBroad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company leveraging DeepMind's AlphaFold and related models. A much larger and better-capitalized incumbent operating in the same AI-for-drug-discovery space.
- Ginkgo Bioworks: Synthetic biology platform company combining automated labs with AI to engineer organisms. Comparable as an AI + biology platform targeting R&D, though with a broader industrial biotech remit.
Emerging players
- Owkin: AI biotech combining federated learning on patient data with drug discovery and development. Adjacent overlap on biomedical data integration and AI-driven target identification.
- Altos Labs: Well-capitalized longevity biotechnology company focused on cellular rejuvenation programming. Direct peer in the aging/age-related disease therapeutic mission, with substantially more capital and scientific scale.
Direct peers
- Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to accelerate therapeutic development. Direct competitor to Mozi in AI-enabled pharma R&D, though operating at significantly larger scale and capital base.
- Recursion Pharmaceuticals: AI-enabled drug discovery platform combining automated wet-lab experiments with machine learning to map biology and identify novel therapeutics. Closely comparable in mission and architecture, with established pharma partnerships (e.g., Roche, Bayer).
- Schrödinger: Computational chemistry and molecular simulation platform used for drug discovery across pharma and biotech. Direct peer in AI-driven molecular design and predictive modeling, serving overlapping customer base.
- BenevolentAI: AI-driven drug discovery company using knowledge graphs and machine learning to identify new drug targets. Closely analogous architecture to Mozi's knowledge-graph approach.
- Exscientia: AI-driven precision medicine company focused on end-to-end drug discovery using AI-designed molecules. Comparable in applying AI to compress drug discovery timelines for pharma partners.
- Insilico Medicine: AI-driven drug discovery company with end-to-end platforms for target identification, generative chemistry, and clinical prediction. Closely comparable to Mozi in applying AI to aging and age-related disease pipelines.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Rejuve.Bio social profiles
Digital presenceRejuve.Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rejuve.Bio leadership team
Management profileNumber of profiles
Profiles6 records
Rejuve.Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rejuve.Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rejuve.Bio
What does Rejuve.Bio do?
Rejuve.Bio builds and operates Mozi, an AI-driven biomedical research platform that unifies genetic, clinical, and preclinical datasets into a knowledge graph, generates testable therapeutic hypotheses using neural-symbolic AI, and validates them against Methuselah Fly outcomes and human health data from the Rejuve Network. The company targets pharmaceutical and biotech researchers working on aging and age-related diseases, and supplements this enterprise platform with the consumer-facing Rejuve.AI app that collects token-incentivized holistic health data.
Is Rejuve.Bio a public or private company?
Rejuve.Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Rejuve.Bio founded?
Rejuve.Bio was founded in 2022. It employs 1 to 10 people.
Where is Rejuve.Bio based?
Rejuve.Bio is headquartered in Orange, United States, in the North America region.
Who are Rejuve.Bio's main competitors?
Broad incumbents on record are Isomorphic Labs and Ginkgo Bioworks. Emerging players are Owkin and Altos Labs. Direct peers are Insitro, Recursion Pharmaceuticals, Schrödinger, BenevolentAI, Exscientia and Insilico Medicine.
Does Rejuve.Bio have an API?
No public API is recorded for Rejuve.Bio.
What industry is Rejuve.Bio in?
Rejuve.Bio's product category is AI-driven drug discovery platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 5417 and its SIC code is 8731.